Literature DB >> 10235090

Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia.

F J Raal1, G J Pilcher, R Waisberg, E P Buthelezi, M G Veller, B I Joffe.   

Abstract

This study's aim was to determine whether biochemical risk factors such as lipoprotein(a), fibrinogen, homocysteine, and insulin, as well as low-density lipoprotein (LDL) particle size, were predictive of carotid intimamedia thickness (IMT), an early marker of atherosclerosis, in subjects with familial hypercholesterolemia (FH). We also determined whether plasma 8-isoprostane, as a marker of in vivo lipid oxidation, correlated with carotid IMT. Twenty-two homozygous and 20 heterozygous subjects with FH were compared with 20 normocholesterolemic controls. On univariate analysis, plasma total and LDL cholesterol, the cholesterol-years score (CYS), lipoprotein(a), and fibrinogen, but not homocysteine or insulin, were positively related, and high-density lipoprotein (HDL) cholesterol was negatively related to carotid IMT. However, on multivariate analysis, only LDL cholesterol and the CYS predicted carotid IMT (multiple r = 0.82; r2 = 0.68; p <0.0001). The subjects with FH had large rather than small dense LDL particles, and plasma 8-isoprostane levels were not increased. LDL cholesterol and the CYS, or "cholesterol bulk" are the pivotal determinants of atherosclerosis and are the strongest predictors of carotid IMT in FH.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10235090     DOI: 10.1016/s0002-9149(99)00095-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  The role of lipoprotein[a] in atherosclerosis.

Authors:  J D Morrisett
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

2.  Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.

Authors:  H A W Neil; V Seagroatt; D J Betteridge; M P Cooper; P N Durrington; J P Miller; M Seed; R P Naoumova; G R Thompson; R Huxley; S E Humphries
Journal:  Heart       Date:  2004-12       Impact factor: 5.994

3.  The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.

Authors:  Melroy X Miranda; Lambertus J van Tits; Christine Lohmann; Tasneem Arsiwala; Stephan Winnik; Anne Tailleux; Sokrates Stein; Ana P Gomes; Vipin Suri; James L Ellis; Thomas A Lutz; Michael O Hottiger; David A Sinclair; Johan Auwerx; Kristina Schoonjans; Bart Staels; Thomas F Lüscher; Christian M Matter
Journal:  Eur Heart J       Date:  2014-03-06       Impact factor: 29.983

Review 4.  Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.

Authors:  Brian A Ference; Henry N Ginsberg; Ian Graham; Kausik K Ray; Chris J Packard; Eric Bruckert; Robert A Hegele; Ronald M Krauss; Frederick J Raal; Heribert Schunkert; Gerald F Watts; Jan Borén; Sergio Fazio; Jay D Horton; Luis Masana; Stephen J Nicholls; Børge G Nordestgaard; Bart van de Sluis; Marja-Riitta Taskinen; Lale Tokgözoglu; Ulf Landmesser; Ulrich Laufs; Olov Wiklund; Jane K Stock; M John Chapman; Alberico L Catapano
Journal:  Eur Heart J       Date:  2017-08-21       Impact factor: 29.983

5.  Compound Heterozygous Familial Hypercholesterolemia Caused by LDLR Variants.

Authors:  Heloisa Pamplona-Cunha; Marcela Freitas Medeiros; Thaís Cristine Marques Sincero; Isabela de Carlos Back; Edson Luiz da Silva
Journal:  Arq Bras Cardiol       Date:  2020-09       Impact factor: 2.667

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.